Malignant pleural mesothelioma: 2013 state of the art]. Bull Cancer (Paris), pp.1283-93, 2013. ,
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005, International Journal of Cancer, vol.26, issue.1, pp.232-240, 1980. ,
DOI : 10.1002/ijc.24711
URL : https://hal.archives-ouvertes.fr/hal-00698003
Mésothéliome pleural malin-Guide du Parcours de Soins. wwwhas-santefr wwwe-cancerfr [serial on the Internet, 2013. ,
Malignant mesothelioma: attributable risk of asbestos exposure., Occupational and Environmental Medicine, vol.51, issue.12, pp.804-815, 1994. ,
DOI : 10.1136/oem.51.12.804
Post-irradiation malignant mesothelioma. Cancer, pp.1379-85, 1996. ,
DOI : 10.1002/(sici)1097-0142(19960401)77:7<1379::aid-cncr24>3.0.co;2-y
Tumours of the pleura. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, 2015. ,
Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases, Virchows Archiv, vol.52, issue.5, 2005. ,
DOI : 10.1007/s00428-005-0035-y
Malignant mesothelioma in Australia, Am J Ind Med, 1945. ,
Malignant mesothelioma: Facts, Myths, and Hypotheses, Journal of Cellular Physiology, vol.57, issue.1, pp.44-58 ,
DOI : 10.1002/jcp.22724
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143206
Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control CCC, pp.935-979, 2009. ,
Health experts concerned over India's asbestos industry, The Lancet, vol.375, issue.9715, pp.626-633, 2010. ,
DOI : 10.1016/S0140-6736(10)60251-6
Recommandations de la Société Française de Pneumologie de Langue Française sur le mésothéliome pleural-Conférence d'experts, 2006. ,
Survie des patients atteints de cancer en France, 2007. ,
DOI : 10.1007/978-2-287-39310-5
URL : https://hal.archives-ouvertes.fr/hal-00434568
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems, Thorax, vol.55, issue.9, 2000. ,
DOI : 10.1136/thorax.55.9.731
Amiante et mésothéliome pleural malin Institut National du Cancer. [Prévention], 2012. ,
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province, Occupational and Environmental Medicine, vol.17, issue.4, pp.260-71, 1960. ,
DOI : 10.1136/oem.17.4.260
The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure, The Annals of Occupational Hygiene, vol.44, issue.8, pp.565-601, 2000. ,
DOI : 10.1016/S0003-4878(00)00045-4
Asbestos-induced lung diseases: an update, Translational Research, vol.153, issue.4, pp.143-52, 2009. ,
DOI : 10.1016/j.trsl.2009.01.004
Update on the molecular biology of malignant mesothelioma. Cancer, 2007. ,
Asbestos, Lung Cancers, and Mesotheliomas, American Journal of Respiratory Cell and Molecular Biology, vol.42, issue.2, pp.133-142, 2010. ,
DOI : 10.1165/rcmb.2009-0206TR
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822975
Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. Feb, vol.1, issue.2, pp.169-71, 2006. ,
Predicting survival in malignant mesothelioma, European Respiratory Journal, vol.38, issue.6, pp.1420-1424, 2011. ,
DOI : 10.1183/09031936.00000811
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma, Modern Pathology, vol.15, issue.2, pp.260-71, 2012. ,
DOI : 10.1158/0008-5472.CAN-09-3993
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, European Respiratory Journal, vol.35, issue.3, pp.23-45, 2010. ,
DOI : 10.1183/09031936.00063109
M??soth??liome??: les dispositifs en place en France ????le r??seau m??soth??liome???? 1998???2013, Annales de Pathologie, vol.34, issue.1, pp.51-63, 1998. ,
DOI : 10.1016/j.annpat.2014.01.009
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Archives of Pathology & Laboratory Medicine, vol.137, issue.5, pp.647-67, 2013. ,
DOI : 10.5858/arpa.2012-0214-OA
Reproducibility of histological subtyping of malignant pleural mesothelioma, Virchows Archiv, vol.23, issue.6, pp.679-85, 2014. ,
DOI : 10.1007/s00428-014-1664-9
Well-differentiated Papillary Mesothelioma of the Pleura, The American Journal of Surgical Pathology, vol.28, issue.4, pp.534-574, 2004. ,
DOI : 10.1097/00000478-200404000-00013
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity, Modern Pathology, vol.19, issue.4, pp.514-537, 2006. ,
DOI : 10.1038/modpathol.3800534
Problems in mesothelioma diagnosis, Histopathology, vol.48, issue.1, pp.55-68, 2009. ,
DOI : 10.1111/j.1365-2559.2008.03178.x
Sarcomatoid mesothelioma: a clinical???pathologic correlation of 326 cases, Modern Pathology, vol.22, issue.3, pp.470-479, 2010. ,
DOI : 10.1046/j.1365-2559.41.s2.41.x
The Separation of Benign and Malignant Mesothelial Proliferations, Archives of Pathology & Laboratory Medicine, vol.136, issue.10, pp.1183-200, 2000. ,
DOI : 10.5858/arpa.2012-0112-RA
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies, Journal of Clinical Pathology, vol.55, issue.9, pp.662-670, 2002. ,
DOI : 10.1136/jcp.55.9.662
Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma, The American Journal of Surgical Pathology, vol.25, issue.1, pp.43-50, 2001. ,
DOI : 10.1097/00000478-200101000-00004
Mesothelial markers in high-grade breast carcinoma, Histopathology, vol.98, issue.5, pp.957-64, 2011. ,
DOI : 10.1111/j.1365-2559.2011.04036.x
Application of mesothelin immunostaining in tumor diagnosis, Am J Surg Pathol, 2003. ,
A Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases, American Journal of Clinical Pathology, vol.130, issue.5, 2008. ,
DOI : 10.1309/AJCPHSUJ15NEYMIP
The Fake Fat Phenomenon in Organizing Pleuritis, The American Journal of Surgical Pathology, vol.35, issue.12, 2011. ,
DOI : 10.1097/PAS.0b013e31822a2481
A Comprehensive Genome-Based Mutational Analysis by Next Generation Sequencing Technology in Patients With Malignant Pleural and Peritoneal Mesothelioma, International Journal of Radiation Oncology*Biology*Physics, vol.93, issue.3 ,
DOI : 10.1016/j.ijrobp.2015.07.444
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing, Journal of Thoracic Oncology, vol.11, issue.10, 2016. ,
DOI : 10.1016/j.jtho.2016.05.020
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration, Cancer Biology & Therapy, vol.50, issue.3, pp.328-363, 2016. ,
DOI : 10.1038/nrc1299
Differential gene expression in mesothelioma, FEBS Letters, vol.49, issue.2-3, pp.2-395, 2000. ,
DOI : 10.1016/S0014-5793(00)01913-X
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nature Genetics, vol.8, issue.4, pp.407-423 ,
DOI : 10.1101/gr.133744.111
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nature Genetics, vol.3, issue.7, 2011. ,
DOI : 10.1186/gb-2007-8-11-r232
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment, Clinical Cancer Research, vol.18, issue.17, pp.4485-90, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2375
Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma, Cancer Science, vol.29, issue.5, pp.868-74 ,
DOI : 10.1111/j.1349-7006.2012.02223.x
BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study, Journal of Thoracic Oncology, vol.11, issue.11, 2016. ,
DOI : 10.1016/j.jtho.2016.06.020
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?, Archives of Pathology & Laboratory Medicine, vol.140, issue.4, pp.318-339 ,
DOI : 10.5858/arpa.2015-0240-SA
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas, The American Journal of Surgical Pathology, vol.40, issue.5, 2016. ,
DOI : 10.1097/PAS.0000000000000616
Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation, Annals of Oncology, vol.24, issue.8, pp.2147-50, 2013. ,
DOI : 10.1093/annonc/mdt135
Germline BAP1 mutations predispose to malignant mesothelioma, Nature Genetics, vol.55, issue.10, pp.1022-1027, 2011. ,
DOI : 10.1038/onc.2009.455
Emerging clinical applications of selected biomarkers in melanoma, Clin Cosmet Investig Dermatol, vol.8, pp.35-46, 2015. ,
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs, Journal of Translational Medicine, vol.10, issue.1, p.179, 2012. ,
DOI : 10.1002/cncr.10159
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas, Clin Cancer Res Off J Am Assoc Cancer Res, vol.9, issue.6, pp.2108-2121, 2003. ,
Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer Amst Neth, pp.131-137, 2002. ,
Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer Amst Neth, 2005. ,
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens, The American Journal of Surgical Pathology, vol.40, issue.1, pp.120-126, 2016. ,
DOI : 10.1097/PAS.0000000000000529
p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma, The American Journal of Surgical Pathology, vol.38, issue.5, pp.681-689, 2014. ,
DOI : 10.1097/PAS.0000000000000176
Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis, American Journal of Clinical Pathology, vol.139, issue.1, 2013. ,
DOI : 10.1309/AJCPT94JVWIHBKRD
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas, Virchows Archiv, vol.16, issue.6, pp.627-662, 2008. ,
DOI : 10.1007/s00428-008-0689-3
World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the, 2004. ,
L'analyse des mutations du g??ne p53 dans les cancers humains : le lien entre l'??pid??miologie et la carcinogen??se., m??decine/sciences, vol.16, issue.12, pp.1387-96, 2000. ,
DOI : 10.4267/10608/1594
Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study, Journal of Thoracic Oncology, vol.10, issue.3, pp.492-501 ,
DOI : 10.1097/JTO.0000000000000436
Patterns of p53 immunoreactivity in endometrial carcinomas: ???all or nothing??? staining is of importance, Histopathology, vol.23, issue.4, pp.786-794, 2011. ,
DOI : 10.1111/j.1365-2559.2011.03907.x
Novel staining pattern of p53 in Barrett???s dysplasia - the absent pattern, Histopathology, vol.15, issue.Suppl. I, pp.933-938, 2010. ,
DOI : 10.1111/j.1365-2559.2010.03715.x
Pitfalls in immunohistochemical validation of tumor marker expression ??? Exemplified in invasive cancer of the uterine cervix, Gynecologic Oncology, vol.112, issue.1, pp.235-275, 2009. ,
DOI : 10.1016/j.ygyno.2008.09.013
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res, pp.264-273, 2015. ,
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2, Histopathology, vol.3, issue.3, pp.231-239, 2003. ,
DOI : 10.1046/j.1365-2559.1997.2150833.x
Running GAGs: myxoid matrix in tumor pathology revisited: What's in it for the pathologist? Virchows Arch, Feb, vol.456, issue.2, pp.181-92, 2010. ,
Diffuse malignant mesothelioma of the pleura: A clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival, Virchows Archiv A Pathological Anatomy and Histopathology, vol.22, issue.6, pp.445-51, 1993. ,
DOI : 10.1007/BF01606452
Malignant Peritoneal Mesothelioma in Women, American Journal of Clinical Pathology, vol.123, issue.5, pp.724-761, 2005. ,
DOI : 10.1309/2H0NVRERPP2LJDUA
Clinicopathologic Characteristics of Malignant Mesotheliomas Arising in Patients With a History of Radiation for Hodgkin and Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.31, issue.36, pp.4544-4553, 2013. ,
DOI : 10.1200/JCO.2013.49.9616
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA, Journal of Clinical Pathology, vol.14, issue.Suppl. 1, pp.854-61, 2013. ,
DOI : 10.1136/jclinpath-2013-201609
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients, Cancer Immunology, Immunotherapy, vol.137, issue.12, pp.1721-1729, 2011. ,
DOI : 10.1007/s00262-011-1073-8
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers, OncoImmunology, vol.34, issue.6, p.1009285, 2015. ,
DOI : 10.1002/(SICI)1097-0258(20000115)19:1%3c113::AID-SIM245%3e3.0.CO;2-O
Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma, PLoS ONE, vol.44, issue.9, p.106742, 2014. ,
DOI : 10.1371/journal.pone.0106742.t002
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas, Human Pathology, vol.52, pp.9-18 ,
DOI : 10.1016/j.humpath.2016.01.010
Germline Gene Mutation in Young Uveal Melanoma Patients, Ophthalmic Genetics, vol.36, issue.2, pp.126-157 ,
DOI : 10.1002/(SICI)1097-0215(19990730)82:3<325::AID-IJC3>3.0.CO;2-G
BAP1: gene of the month, J Clin Pathol, 2016. ,
Extensive myxoid change in well-differentiated papillary mesothelioma of the pelvic peritoneum, Annals of Diagnostic Pathology, vol.6, issue.3, pp.164-171, 2002. ,
DOI : 10.1053/adpa.2002.33902